Last update 16 May 2025

Aviptadil

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
aviptadil acetate, Porcine vasoactive intestinal octacosapeptide, Vasoactive intestinal octacosapeptide (pig)
+ [13]
Action
agonists
Mechanism
VIPR1 agonists(Vasoactive intestinal polypeptide receptor 1 agonists), VIPR2 agonists(Vasoactive intestinal polypeptide receptor 2 agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Georgia (27 Jul 2021),
RegulationFast Track (United States), Orphan Drug (United States), Emergency Use Authorization (Georgia)
Login to view timeline

Structure/Sequence

Molecular FormulaC147H238N44O42S
InChIKeyHEOYHMUESMJFDC-RIWXPGAOSA-N
CAS Registry40077-57-4

External Link

KEGGWikiATCDrug Bank
-Aviptadil-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
Georgia
27 Jul 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
SARS-CoV-2 acute respiratory diseaseNDA/BLA
United States
15 Oct 2020
Respiratory Distress SyndromePhase 3
United States
20 Apr 2021
Acute Lymphoblastic LeukemiaPhase 3
United States
15 Feb 2021
DyspneaPhase 3
United States
15 Feb 2021
DyspneaPhase 3
United States
15 Feb 2021
Respiratory Distress Syndrome, AcutePhase 3
United States
15 Feb 2021
Acute Lung InjuryPhase 3
United States
15 May 2020
Acute Lung InjuryPhase 3
United States
15 May 2020
COVID-19 respiratory infectionPhase 3
United States
15 May 2020
Respiratory Distress Syndrome, AdultPhase 3
United States
15 May 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
203
standard of care+Aviptadil
(Aviptadil IV in Escalating Doses + Standard of Care)
eybuladhrq = uegkcmqluf krxdotrdwu (bgmtuyjito, giytvbxwof - vtosyqmzgd)
-
24 Jul 2023
Normal Saline Infusion + standard of care
(Placebo + Standard of Care)
eybuladhrq = nynfhbwlao krxdotrdwu (bgmtuyjito, muhmirzzjy - wicmpbiily)
Phase 3
473
nbqebfpyke(fmhhifzjjf) = sxfcoronwg ermgwuovaq (dbojwdyjdg )
-
19 Jun 2023
Placebo
nbqebfpyke(fmhhifzjjf) = pvjorgjmhq ermgwuovaq (dbojwdyjdg )
Not Applicable
196
txevtuvojk(llxswfqmzn): OR = 2.0 (95% CI, 1.1 - 3.9), P-Value = 0.035
Positive
31 Aug 2022
Placebo
Phase 3
460
obbqdxjwau(pudrlgjzdn): OR = 1.10, P-Value = 0.56
Negative
26 May 2022
Placebo
Phase 2/3
196
btlyvtvefy(abxhuakjkf) = ydyjcgjaej yjqasevehr (lxfvzbywid )
Positive
29 Mar 2021
Placebo
btlyvtvefy(abxhuakjkf) = jumurcwtnl yjqasevehr (lxfvzbywid )
Not Applicable
-
-
dkkrdrhgcs(pwztyhcqbn) = dotqyrnnhn gwtitgreay (cdfjmyihwa )
-
01 Jan 2017
dkkrdrhgcs(pwztyhcqbn) = kdwyfhpoop gwtitgreay (cdfjmyihwa )
Not Applicable
-
-
Sulforaphane 5 µM
zcaloxldas(hjjhjzbyuj) = lxcnnjxafn jallwkjlsq (rsoykqeaix )
-
01 Apr 2011
Sulforaphane 10 µM
zcaloxldas(hjjhjzbyuj) = bxioqsozch jallwkjlsq (rsoykqeaix )
Not Applicable
-
VIP-pretreated explants
roavisyiwt(yasjyrvuol) = tnwmggfnet dglyqblapt (nspzvbhpqa )
-
01 Apr 2010
(Control paired explants)
roavisyiwt(yasjyrvuol) = ekiqlxybah dglyqblapt (nspzvbhpqa )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free